

1 **Title:** Risk Factors of Multi-Drug Resistant Tuberculosis among Tuberculosis Patients in
2 Province 3, Nepal: A case-control study

3 **Short title:** MDR-TB Risk Factors in Nepal

4 **Authors:** Puspa Acharya^{1*}, Niraj Bhattarai², Bhuban Raj Kunwar³, Khem Raj Sharma⁴, Vijay
5 Kumar Khanal⁴, Birendra Kumar Yadav⁴

6 **Affiliations:** ¹Department of Public Health, Shree Birendra Hospital, Chhauni, Kathmandu,
7 Nepal; ²Nepal Development Society, Kathmandu, Nepal; ³ Department of Anesthesia, Shree
8 Birendra Hospital, Chhauni, Kathmandu, Nepal; ⁴ B.P Koirala Institute of Health Sciences,
9 Dharan, Sunsari Nepal

10 **Email address of authors:** puspacharyas@gmail.com [P. Acharya], bniraj80@gmail.com
11 [N.Bhattarai], drbrkunwar@yahoo.com [B.R. Kunwar], Khemraja@gmail.com [KR.Sharma],
12 vijay.khanal@bпкиh.edu [VK. Khanal], bkyadav1@gmail.com [BK. Yadav]

13

14 ***Corresponding author:** puspacharyas@gmail.com [P. Acharya]

15

16 **Abstract**

17

18 **Background:** Drug-resistant tuberculosis poses a significant threat to global TB control
19 efforts, potentially reversing progress made in reducing TB-related morbidity and mortality.
20 This study aims to identify risk factors for multidrug-resistant TB [MDR-TB] in Province 3,
21 Nepal.

22

23 **Methodology:** A case-control study was conducted by matching TB-infected patients
24 undergoing MDR-TB treatment and DS-TB treatment by gender. Data was collected through
25 structured questionnaires and interviews and analyzed using binary logistic regression.

26

27 **Results:** Significant risk factors for MDR-TB included Pulmonary Tuberculosis [PTB],
28 previous TB treatment history, close contact with DR-TB patients, and subjective feelings of
29 sadness.

30

31 **Conclusion:** The study highlights the importance of prevention measures to break transmission
32 chains and infection control in health facilities. Additionally, it underscores the need for mental
33 health support for TB patients.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

34 **Keywords:** MDR-TB, Risk Factors, Previous Treatment History

35

36 **Introduction**

37

38 Tuberculosis [TB] is the most common cause of death worldwide and the leading cause of
39 death from a single infectious agent, even exceeding HIV/AIDS. An estimated 10.0 million
40 [range, 9.0– 11.1 million] people fell ill with TB in 2018; there were 1.2 million TB deaths
41 among HIV-negative people in 2018 and a further 2,51,000 deaths among HIV-positive
42 people(1).In April 1993, the World Health Organization [WHO] declared tuberculosis a public
43 health emergency[2]. After defining the nature and size of the global TB problem, WHO
44 introduced the Directly Observed Treatment Short-course [DOTS] as a solution to an
45 emergency[3]. The expanding HIV epidemic and the growth of drug-resistant tuberculosis
46 [DR-TB] further subverted the DOTS strategy, which was hampered by imprecise diagnostic
47 tools and passive case detection(4).

48 Antimicrobial Resistance [AMR] is an increasingly significant threat to public health, and the
49 rise of AMR coincides with the development of TB (5,6). The rise of drug-resistant tuberculosis
50 has the potential to reverse progress made to scale back tuberculosis-related morbidity and
51 mortality over the past 20 years. Drug resistance emerges as a result of inadequate tuberculosis
52 treatment, which could be an incorrect combination of tuberculosis drugs, inadequate dose or
53 duration, or irregular drug-taking. These problems can occur in any setting but are particularly
54 prevalent in poorly regulated non-public sectors(7). Multi-drug resistant tuberculosis [MDR-
55 TB] is tuberculosis that is resistant to at least two first-line drugs, isoniazid and
56 rifampicin(8).TB strains with DR-TB are harder to treat than drug-susceptible ones and also
57 take much longer(9). Globally, only half of the MDR-TB patients are treated successfully; the
58 other half are at high risk of either not surviving or continuing to transmit the disease and
59 threaten global progress towards the targets set by the End TB Strategy of the World Health
60 Organization [WHO](4). Globally, in 2018, an estimated 3.4% [95% confidence interval [CI]:
61 2.5–4.4%] of new cases and 18% [95% CI: 7.6–31%] of previously treated cases had MDR/RR-
62 TB. There were 484,000 [range, 417,000–556,000] incident cases of MDR/RR-TB in 2018,
63 and only 32% of the estimated patients were enrolled in treatment. The highest proportions are
64 in several countries of the former Soviet Union [above 25% in new cases and above 50% in
65 previously treated cases. World Health Organization [WHO] has recently updated the guidance
66 on DR-TB treatment by including Levofloxacin [a fluoroquinolone] and pyrazinamide as a

67 component of the treatment regimens for MDR/RR-TB and isoniazid-resistant, rifampicin-
68 susceptible TB [Hr-TB](1). As MDR-TB involves more extensive and longer treatment courses
69 than drug-susceptible TB, households with multidrug resistances are at a particularly greater
70 risk of incurring catastrophic costs(10). The percentage facing catastrophic total costs ranged
71 from 27% to 83% for all forms of TB and from 67% to 100% for drug-resistant TB (1). The
72 disease can affect anyone anywhere, but most people who develop TB [about 90%] are adults,
73 and the male: female ratio is 2:1[1]; long-term exposure to ambient SO₂ is likely to increase
74 the risk of TB in males(11). Global targets and milestones for reducing the burden of TB
75 disease have been set as part of the Sustainable Development Goals [SDGs] and the World
76 Health Organization's End TB Strategy, and seven countries with high TB burdens were also
77 on track to achieve 2020 END TB milestones during this period (1).

78
79 Tuberculosis [TB] remains a serious public health problem in the South-East Asia Region
80 [SEAR] as well (12). DR-TB burden was higher in India [27%], China [14%] and the Russian
81 Federation [9%] in 2018(1).TB is also the leading cause of disability-adjusted life years
82 [DALYs] lost among people in the region among all communicable diseases, affecting the
83 productive age group of the countries in SEAR(13). Similarly, Myanmar has over 70% of TSR
84 for MDR-TB and was on track to achieve 2020 END TB milestones.(1).

85
86 It has been predicted that deaths attributable to AMR could rise more than tenfold to 10 million
87 annually by 2050. Unless action is taken now, DR-TB could be responsible for about 2.5
88 million of these deaths(14). A global total of 186 772 cases of multidrug-resistant TB or
89 rifampicin-resistant TB [MDR/RR-TB] were notified in 2018, up from 160 684 in 2017, and
90 156 071 cases were enrolled in treatment, up from 139 114 in 2017. Despite these
91 improvements, only 32% of the estimated 484,000 cases [range 417,000–556,000] were
92 enrolled in treatment in 2018(1). The uncontrolled TB burden impacts socio-economic
93 development and increases drug resistance in the SEAR region (15). If tuberculosis
94 management practices across sectors in India remain unchanged over the next 20 years, it is
95 estimated a 47% increase in the incidence of isoniazid resistance, a 152% increase in MDR-
96 TB incidence, a 242% increase in prevalent untreated multidrug-resistant tuberculosis, and a
97 275% increase in the risk of multidrug-resistant tuberculosis infection(7).

98
99 In Nepal, there are approximately 1500 [0.84 to 2.4] cases of DR-TB annually, and only 350

100 to 450 MDR-TB cases are reported annually. So, the missing cases are the major problem in
101 Nepal(8). There are major challenges for diagnosis of MDR TB in Nepal, such as inadequate
102 training, frequent power failure, difficulty in maintaining an appropriate steady temperature,
103 module failure, which is often not replaced in time, issues with calibration and timely
104 availability of cartridges, as well as appropriate ways to store the new cartridges and safe
105 disposal of the used cartridges (16). From a public health perspective, the MDR-TB growing
106 epidemics will not be controlled merely by the introduction of a few new antibiotics as it is
107 also linked to patient compliance and adequate case management supported by efficient TB
108 programs(17). Deaths from drug-resistant TB now account for about one-third of all
109 antimicrobial resistance deaths worldwide. Treating DR-TB is costlier and may take three to
110 fourfold as long as not all people will survive.(6). The latest treatment outcome data for people
111 with MDR/RR-TB showed a global treatment success rate of only 56%(1).

112 As MDR-TB involves more extensive and longer treatment courses than drug-susceptible TB,
113 households with multidrug resistance are at a particularly greater risk of incurring catastrophic
114 costs. The study identified the factors associated with resistance that might assist concerned
115 authorities in focusing efforts on those factors in the community. This might help prevent and
116 control tuberculosis and MDR-TB by influencing Public Health Policy. As MDR-TB involves
117 more extensive and longer treatment courses than drug-susceptible TB, households with
118 multidrug resistance are at a particularly greater risk of incurring catastrophic costs. Hence,
119 ending TB will benefit the poorest ones.(10). This study aims to assess the risk factors of Multi-
120 Drug-Resistant Tuberculosis among Tuberculosis patients of Province 3, Nepal.

121

122 **METHODS**

123

124 The study used a case-control design to evaluate the risk of MDR-TB, which was conducted in
125 Province 3, Nepal, which is known for its high MDR-TB burden. Cases comprised confirmed
126 MDR-TB patients undergoing treatment at selected MDR treatment centres and sub-centres in
127 Kathmandu, Bhaktapur, and Chitwan. At the same time, controls consisted of TB patients
128 receiving anti-tuberculosis drugs at designated DOTS centres in the same districts. Inclusion
129 criteria for cases required confirmation of MDR-TB through records from the MDR-TB
130 treatment center, while controls encompassed pulmonary and extra-pulmonary TB patients on
131 anti-tuberculosis medication. Exclusions were applied to severely ill patients who were unable
132 to participate and those under 15 years old. The study adhered to ethical considerations,

133 received clearance from the institutional review committee, and obtained informed verbal
134 consent from respondents, ensuring confidentiality and data integrity. The researcher also took
135 permission from the National Tuberculosis Control Centre, Thimi Bhaktapur, to conduct this
136 research in the selected study sites after receiving IRC clearance. The structured questionnaire
137 was prepared after a substantial literature review, and a piloting study was done among TB
138 patients of BPKIHs, Dharan, by obtaining verbal consent from the participants. The study was
139 conducted from March 2021 to August 2021. The operational definition used in the study is
140 included as a supplementary document.

141

142 **Sampling Technique:**

143

144 The three districts were selected randomly, and all the DR-TB centres from these districts were
145 included in the study. The subjects who gave consent were interviewed. Cases were selected
146 from these DR-TB treatment centres/subcentre such as Nepal Anti-TB Association-
147 Kathmandu, Japan Nepal Tuberculosis Research association-Kathmandu, National
148 Tuberculosis Control centre-Bhaktapur, Nepal Anti-TB Association- Chitwan. All the DS-TB
149 cases with approved verbal consent were interviewed. DOTS centres such as Manmohan
150 Memorial Medical College and Teaching Hospital- Kathmandu, Nagarik Community Hospital-
151 Bhaktapur, Bharatpur Health office, Parbatipur Health Post, Genetup-Kathmandu, JANTRA-
152 Kathmandu, NATA-Chitwan were selected for this study.

153

154 **Calculation of the sample size:**

155 The study period was fixed for six months, and during the study periods, all the laboratory-
156 confirmed and registered DR-TB patients were asked to participate from all treatment
157 centres/sub-centres in selected districts—Chitwan, Kathmandu, and Bhaktapur. Despite
158 approximately 85 DR-TB patients across these districts, only 77 agreed to participate. All the
159 DS-TB cases were also interviewed, and gender matching was ensured using SPSS, resulting
160 in a final sample size of 154 respondents, maintaining a 1:1 ratio of cases to controls.

161

162 **Data Collection Techniques**

163

164 Amidst the challenges posed by the COVID-19 pandemic, a second wave in Nepal, a face-to-
165 face interview was undertaken to collect data from both cases and controls. The clinical

166 attributes of the participants were meticulously validated against their laboratory records.
167 Despite the pandemic's constraints, conducting interviews proved to be difficult. However, the
168 institution provided a designated counselling room, coupled with the use of appropriate
169 personal protective equipment [PPE] and adherence to social distancing measures; data
170 collection was successfully facilitated. Recent episodes of TB history were taken to avoid recall
171 bias, and a researcher collected data herself to minimise interviewer variations.

172

173 **Data Management and Analysis**

174 Data entry was conducted using Microsoft Excel and subsequently transferred to SPSS version
175 16 for statistical analysis. Before entry, numerical coding was manually prepared based on the
176 nature of the data, and regular cross-checking ensured accuracy, with verification after every
177 ten entries. Descriptive statistics, Frequency, and percentages were employed to present case
178 and control frequencies. The inferential analysis utilised chi-square tests for categorical
179 nominal data association and binary regression analysis for variables potentially predictive of
180 MDR-TB, with significance set at $p < 0.05$ and 95% confidence intervals. Factors exhibiting a
181 p-value less than 0.020 in bivariate analysis underwent binary logistic regression for further
182 analysis after adjusting confounders.

183 **Variables of the**

184 **study:**

185 **Independent variable**

- 186 ✓ Age
- 187
- 188 ✓ Gender
- 189
- 190 ✓ Weight
- 191
- 192 ✓ Marital status
- 193
- 194 ✓ Residence
- 195
- 196 ✓ Education
- 197
- 198 ✓ Occupation
- 199
- 200 ✓ Monthly income
- 201

- 202 ✓ Ethnicity
- 203
- 204 ✓ Religion
- 205
- 206 ✓ Family type
- 207
- 208 ✓ Co- Morbid (HIV/AIDS & Other diseases)
- 209
- 210 ✓ stigma
- 211
- 212 ✓ social isolation
- 213
- 214 ✓ Means of transportation
- 215
- 216 ✓ Subjective feelings of sadness
- 217

218 **Associated factors**

219

- 220 ✓ Types of TB
- 221
- 222 ✓ Previous History of TB
- 223
- 224 ✓ Interruption of TB treatment
- 225
- 226 ✓ Contact with TB patients
- 227
- 228 ✓ Contact with DR TB patients
- 229
- 230 ✓ Response to Treatment Phase
- 231
- 232 ✓ Counselling session
- 233

234 **Dependent variable**

235

- 236 ✓ Multi Drug Resistant Tuberculosis (MDR-TB)

237

238 **RESULTS**

239

240 Table 1 illustrates demographic and socio-economic characteristics between cases and controls.
241 While both groups have similar gender distributions, with males representing 55.8% and
242 females 44.2%, the control group has a higher proportion of individuals under 35 years [64.9%]
243 compared to the case group [58.4%]. Marital status and ethnicity are largely comparable, but

244 there are differences in residence, education, and employment status. The control group has
 245 more residents in metropolitan cities [62.3% vs. 41.6% in cases] and fewer in rural areas
 246 [13.0% vs. 37.7% in cases]. Additionally, a higher percentage of cases are unemployed [44.2%
 247 vs. 33.8% in controls] and more are students [24.7% vs. 31.2% in controls]. Access to health
 248 facilities within 30 minutes is higher in the control group [96.1% vs. 66.2% in cases], and they
 249 utilize private health facilities more [85.7% vs. 58.8% in cases].

250 **Table 1: Demographic and Socio-economic characteristics of respondents.**

Characteristics	Case [n=77] Frequency [n]	Percentage [%]	Control Frequency [n]	[n=77] Percentage [%]
Age				
< 35	45	[58.4%]	50	[64.9%]
≥ 35	32	[41.6%]	27	[35.1%]
Gender				
Male	43	[55.8%]	43	[55.8%]
Female	34	[44.2%]	34	[44.2%]
Marital status				
Unmarried	32	[41.60%]	35	[45.50%]
Married	43	[55.80%]	41	[53.20%]
Widow	1	[1.30%]	1	[1.30%]
Widower	1	[1.30%]	0	[0.00%]
Residence				
Metropolitan city	32	[41.6%]	48	[62.3%]
Municipality	16	[20.8%]	19	[24.7%]
Rural Municipality	29	[37.7%]	10	[13.0%]
Education				
Uneducated	5	[6.5%]	5	[6.5%]
Primary level	22	[28.6%]	13	[16.9%]
Secondary level	20	[26.0%]	28	[36.4%]
Higher level education	30	[39.0%]	31	[40.3%]
Occupation				
Unemployed	34	[44.2%]	26	[33.8%]
Formal sector employee	10	[13.0%]	15	[19.5%]
Informal sector employee	14	[18.2%]	12	[15.6%]
Student	19	[24.7%]	24	[31.2%]
Monthly Income of employed respondents [n= 51]				
< Rs 24000	12	[50%]	15	[55.6%]
≥ Rs 24000	12	[50%]	12	[44.4%]
Ethnicity				
Dalit	2	[2.6%]	4	[5.2%]
Janajati	41	[53.2%]	41	[53.2%]
Madhesi	2	[2.6%]	1	[1.3%]
Muslim	3	[3.9%]	1	[1.3%]
Brahmin/Chhetri	29	[37.7%]	29	[37.7%]

Others	0	[0.0%]	1	[1.3%]
Religion				
Hindu	57	[74.0%]	65	[84.4%]
Buddhist	17	[22.1%]	8	[10.4%]
Muslim	3	[3.9%]	1	[1.3%]
Christian	0	[0.0%]	3	[3.9%]
Family Type				
Nuclear	39	[50.60%]	46	[59.70%]
Joint	36	[46.80%]	30	[39.00%]
Extended	2	[2.60%]	1	[1.30%]
Presence of Adequate Ventilation				
No	20	[25.9%]	8	[10.3%]
Yes	57	[74.1%]	69	[89.7%]
Recent Migration				
No	35	[45.5%]	50	[64.9%]
Yes	42	[54.5%]	27	[35.1%]
Types of Migration				
Internal Migration	37	[88.1%]	23	[85.2%]
External Migration	5	[11.9%]	4	[14.8%]
Time to reach Health Facilities				
Less than 30 minutes	51	[66.2%]	74	[96.1%]
Greater than 30 minutes	26	[33.8%]	3	[3.9%]
Means of Transportation				
Cycle	1	[1.3%]	2	[2.6%]
Bike/Scooter	11	[14.3%]	25	[32.5%]
Public Vehicle	64	[83.1%]	41	[53.2%]
By foot	1	[1.3%]	9	[11.7%]
Health-seeking Behavior of patients				
Too late	57	[74.0%]	51	[66.2%]
In time	171	[22.1%]	25	[32.5%]
Early	3	[3.9%]	1	[1.3%]
Treatment Initiation site				
Public Health Facilities	43	[58.8%]	11	[14.3%]
Private Health Facilities	34	[42.2%]	66	[85.7%]

251

252 Table 2 shows that pulmonary TB cases were higher among the cases, at 89.6%, compared to
 253 57.1% in the control group. Conversely, Extra Pulmonary TB cases were more prevalent in the
 254 Controls at 42.9% versus 10.4% in the Cases. Notably, a prior history of TB was significantly
 255 more common among Cases, with 63.6% compared to a mere 10.4% in Controls. Among those
 256 with a TB history, Cases experienced treatment interruptions at a higher rate of 51.0%,
 257 contrasting with just 12.5% in Controls. Reasons for such interruptions varied, with
 258 complications accounting for 8% among Cases and none among Controls, while loss to follow-
 259 up stood at 16% for Cases versus 100% for Controls. Additionally, 25% of Cases switched to

260 MDR treatment compared to none in Controls. Close contact with TB patients was markedly
 261 more prevalent among Cases [64.9%] than Controls [32.5%], with similar trends observed for
 262 contact with DR TB patients. Notably, negative sputum conversion rates were higher among
 263 Cases [79.2%] versus Controls [66.2%]. Hospital stays were significantly more common
 264 among Cases [89.6%] than Controls [31.2%]. Treatment modalities also exhibited disparities,
 265 with 44.2% of Cases receiving treatment after failure compared to none in Controls and 48.1%
 266 of Cases undergoing the intensive treatment phase versus 74.0% of Controls. In terms of TB
 267 treatment categories, Cases predominantly fell into LR1 [58.5%] and LR2 [31.1%] categories,
 268 while Controls were exclusively categorized as CAT I [100%].

269 **Table 2: Clinical Characteristics of Respondents**

Characteristics	Case[n=77] Frequency	Percentage [%]	Control[n=77] Frequency	Percentage [%]
Tuberculosis Types				
Pulmonary TB	69	[89.6%]	44	[57.1%]
Extra Pulmonary TB	8	[10.4%]	33	[42.9%]
Previous history of TB				
No	28	[36.4%]	69	[89.6%]
Yes	49	[63.6%]	8	[10.4%]
If yes, was there any interruption of TB treatment [n= 49 cases, 8 controls]				
No	24	[49.0%]	7	[87.5%]
Yes	25	[51.0%]	1	[12.5%]
Reason for interruption of TB treatment [n= 25 cases, 1 controls]				
Complication	2	[8%]	0	[0%]
Loss to follow up	4	[16%]	1	[100%]
Switch to MDR	5	[25%]	0	[0%]
Site Changed	1	[4%]	0	[0%]
TAF	12	[48%]	0	[0%]
Workload	1	[4%]	0	[0%]
Close contact with TB Patients				
No	27	[35.1%]	52	[67.5%]
Yes	50	[64.9%]	25	[32.5%]
Close contact with DR TB patients				
No	38	[49.4%]	76	[98.7%]
Yes	39	[50.6%]	1	[1.3%]
Response to TB treatment [Sputum Conversion]				
Negative	61	[79.2%]	51	[66.2%]
Positive	16	[20.8%]	26	[33.8%]
Experience of hospital stays				
No	8	[10.4%]	53	[68.8%]
Yes	69	[89.6%]	24	[31.2%]
Registration category of patients				
New	23	[29.9%]	69	[89.6%]
Relapse	26	[20.8%]	8	[10.4%]
Treatment After				

Failure	34	[44.2%]	0	[0.0%]
Treatment after loss to follow-up	2	[2.6%]	0	[0.0%]
Others previously Treated	1	[1.3%]	0	[0.0%]
Previous Treatment History Unknown	1	[1.3%]	0	[0.0%]
Treatment Phase				
Intensive	37	[48.1%]	57	[74.0%]
Continuous	40	[51.9%]	20	[26.0%]
TB Treatment Category				
LR1	45	[58.5%]	0	[0%]
LR2	24	[31.1%]	0	[0%]
LR3	1	[1.3%]	0	[0%]
SSTR	4	[5.2%]	0	[0%]
Others	3	[3.9%]	0	[0%]
CAT I	0	[0%]	77	[100%]

270

271 Table 3 presents psychological and social tuberculosis-related variables [TB] among cases and
 272 controls. In the cases group, 54.5% attended TB counselling sessions, which was notably
 273 higher than 85.7% in the control group. Regarding HIV status, 93.5% of Cases were negative,
 274 compared to 100% of Controls. Additionally, 31.2% of Cases reported having other diseases,
 275 contrasting with 24.7% in the control group. Alcohol consumption was notably prevalent
 276 among Cases at 76.6%, whereas 68.8% of Controls reported the same. Smoking was more
 277 common among Cases [51.9%] than in Controls [18.2%], and similarly, illicit drug use was
 278 higher in Cases [18.2%] than in Controls [2.6%]. The incidence of imprisonment was minimal
 279 in both groups, with Cases slightly higher at 3.9% compared to Controls at 2.6%. Social
 280 isolation was more pronounced among Cases at 53.2% compared to Controls at 39.0%. Cases
 281 also reported higher rates of perceived stigma associated with TB, with 74.0% fearing loss of
 282 friends and employment, 77.9% experiencing social stigma, and 55.8% preferring privacy
 283 regarding their TB status, whereas Controls reported lower rates in these categories.
 284 Furthermore, Cases exhibited higher nervousness levels [76.6%] and sadness [58.4%] than
 285 Controls. Troubles within the past 12 months were reported by 46.8% of Cases and 14.3% of
 286 Controls. Despite challenges, both groups expressed happiness, with 79.2% of Cases and
 287 88.3% of Controls considering themselves happy despite their TB status.

288 **Table 3: Psychological and co-morbidity status of respondents**

Variables	Case [n=77] Frequency [n]	Percentage [%]	Control [n=77] Frequency [n]	Percentage [%]
Attended any TB counselling sessions				
No	35	[45.50%]	11	[14.30%]

Yes	42	[54.50%]	66	[85.70%]
HIV status				
Negative	72	[93.5%]	77	[100.0%]
Positive	5	[6.5%]	0	[00.0%]
Presence of other disease				
No	53	[68.8%]	58	[75.3%]
Yes	24	[31.2%]	19	[24.7%]
Alcohol consumption				
No	18	[23.4%]	24	[31.2%]
Yes	59	[76.6%]	53	[68.8%]
Smoking				
No	37	[48.1%]	63	[81.8%]
Yes	40	[51.9%]	14	[18.2%]
Illicit drug use				
No	63	[81.8%]	75	[97.4%]
Yes	14	[18.2%]	2	[2.6%]
Imprisonment				
No	74	[96.10%]	75	[97.40%]
yes	3	[3.90%]	2	[2.60%]
Social isolation				
No	36	[46.8%]	30	[39.0%]
Yes	41	[53.2%]	47	[61.0%]
I feel that I will lose friends and employment because I have TB				
No	20	[26.0%]	55	[71.4%]
Yes	57	[74.0%]	22	[28.6%]
People look at me differently because I have tuberculosis				
No	17	[22.1%]	49	[63.6%]
Yes	60	[77.9%]	28	[36.4%]
I don't like other people to know that I have TB				
No	34	[44.2%]	24	[31.2%]
Yes	43	[55.8%]	53	[68.8%]
I consider myself nervous				
No	18	[23.4%]	41	[53.2%]
Yes	59	[76.6%]	36	[46.8%]
Sometimes I feel so sad that nothing can cheer me up				
No	32	[41.6%]	68	[88.3%]
Yes	45	[58.4%]	9	[11.7%]
Did something trouble you during the past 12 months?				
No	41	[53.2%]	66	[85.7%]
Yes	36	[46.8%]	11	[14.3%]
Despite of disease, I think I am happy.				
No	16	[20.80%]	16	[11.70%]
Yes	61	[79.20%]	61	[88.30%]

290 Table 4 shows several significant associations highlighting key environmental and socio-
 291 economic factors. Cases group exhibit a notably higher prevalence in rural areas, with 37.7%
 292 residing in rural municipalities compared to only 13.0% of controls [$p = 0.02$]. Recent

293 migration emerges as a significant factor, with 54.5% of Cases reporting recent migration
 294 compared to 35.1% of controls [p = 0.015]. Additionally, inadequate ventilation is more
 295 prevalent among the cases group, with 26.0% reporting inadequate ventilation compared to
 296 10.4% of controls [p = 0.012]. Access to healthcare services is also impacted, as evidenced by
 297 66.2% of cases taking more than 30 minutes to reach health facilities compared to only 3.9%
 298 of controls [p < 0.001]. These findings underscore the critical influence of environmental and
 299 socio-economic determinants on TB prevalence and access to healthcare, emphasizing the
 300 importance of targeted interventions to address these disparities for effective TB prevention
 301 and control strategies.

302 **Table 4 : Key Factors associated with MDR-TB**

Characteristics	Case[n=77] Frequency [%]	Control[n=77] Frequency [%]	P value
Age			
<35	45 [58.4%]	50 [64.9%]	0.407
≥ 35	32 [41.6%]	27 [35.5%]	
Gender			
Male	43 [55.8%]	43 [55.8%]	1.000
Female	34 [44.2%]	34 [44.2%]	
Marital status			
Unmarried	32 [41.60%]	35 [45.50%]	0.468
Married	43 [55.80%]	41 [53.20%]	
Widow	1 [1.30%]	1 [1.30%]	
Widower	1 [1.30%]	0 [0.00%]	
Residence			
Metropolitan city	32 [41.6%]	48 [62.3%]	0.02
Municipality	16 [20.8%]	19 [24.7%]	
Rural Municipality	29 [37.7%]	10 [13.0%]	
Education			
Uneducated	5 [6.5%]	5 [6.5%]	0.30
Primary level	22 [28.6%]	13 [16.9%]	
Secondary level	20 [26.0%]	28 [36.4%]	
Higher level education	30 [39.0%]	31 [40.3%]	
Occupation			
Unemployed	34 [44.2%]	26 [33.8%]	0.591
Formal sector employee	10 [13.0%]	15 [19.5%]	
Informal sector employee	14 [18.2%]	12 [15.6%]	
student	19 [24.7%]	24 [31.2%]	
Ethnicity			
Brahmin/Chhetri	29 [37.7%]	29 [37.7%]	1.000
Others	48[62.3%]	48[62.3%]	
Religion			
Hindu	57 [74.0%]	65 [84.4%]	0.112
Non-Hindu	20 [26.0%]	12 [15.6%]	
Family Type			

Nuclear	39 [50.60%]	46 [59.70%]	0.231
Joint	36 [46.80%]	30 [39.00%]	
Extended	2 [2.60%]	1 [1.30%]	
Adequate ventilation			
No	20 [26.0%]	8 [10.4%]	0.012
Yes	57 [74.0%]	69 [89%]	
Recent Migration			
No	35 [45.5%]	50 [64.9%]	0.015
Yes	42 [54.5%]	27 [35.1%]	
Types of Migration			
Internal Migration	37 [88.1%]	23 [85.2%]	0.729
External Migration	5 [11.9%]	4 [14.8%]	
Time to reach Health Facilities			
Less than 30 minutes	51 [66.2%]	74 [96.1%]	<0.001
Greater than 30 minutes	26 [33.8%]	3 [3.9%]	
Means of Transportation			
Cycle	1 [1.3%]	2 [2.6%]	0.060
Bike/Scooter	11 [14.3%]	25 [32.5%]	
Public Vehicle	64 [83.1%]	41 [53.2%]	
By foot	1 [1.3%]	9 [11.7%]	
Health-seeking Behavior of patients			
Too late	57 [74.0%]	51 [66.2%]	0.53
In time	17 [22.1%]	25 [32.5%]	
Early	3 [3.9%]	1 [1.3%]	

303

304 Table 5 depicted Pulmonary TB as notably more prevalent among cases [89.6%] compared to
305 controls [57.1%], indicating it as a significant risk factor [$p < 0.001$; OR: 6.5; 95% CI: 2.7-
306 15.2]. Conversely, controls exhibited a higher incidence of Extra Pulmonary TB [42.9%]
307 compared to cases [10.4%]. Individuals with a previous TB history were notably more common
308 among cases [63.6%] than controls [10.4%], indicating it as a substantial risk factor [$p < 0.001$;
309 OR: 15.09; 95% CI: 6.34-35.91]. Similarly, cases were more likely to report close contact with
310 TB patients [64.9%] compared to controls [32.5%], showing a significant association [$p <$
311 0.001 ; OR: 3.85; 95% CI: 1.97-7.51] likewise, cases were significantly associated with close
312 contact with drug-resistant TB patients [$p = 0.001$; OR: 78; 95% CI: 10.31-589.62] suggesting
313 the exposure as a risk factor. Cases reported higher levels of perceived stigma, with concerns
314 about losing friends and employment due to TB [$p < 0.001$; OR: 7.12; 95% CI: 3.50-14.49]
315 and feeling that people looked at them differently [$p < 0.001$; OR: 6.17; 95% CI: 3.02-12.57],
316 indicating poor psychosocial health. Additionally, cases exhibited a higher prevalence of
317 nervousness [$p < 0.001$; OR: 3.73; 95% CI: 1.86-7.45] and consistent sadness [$p < 0.001$; OR:
318 10.62; 95% CI: 4.63-24.36], signifying these as factors of concern. These findings highlight
319 the importance of addressing these psychosocial risk factors alongside medical interventions

320 in TB management.

321 **Table 5: Association of MDR–TB with clinical characteristics of the respondents**

322

Categories	Case[n=77]	Control [n=77]	P-value	OR	95% CI [Lower-Upper]
Tuberculosis Types					
Pulmonary TB	69 [89.6%]	44 [57.1%]	<0.001	6.5	2.7-15.2
Extra Pulmonary TB	08 [10.4%]	33 [42.9%]			
Previous history of TB					
Yes	49 [63.6%]	08 [10.4%]	<0.001	15.09	6.34-35.91
No	28 [36.4%]	69 [89.6%]			
If yes, was there any interruption of TB treatment					
Yes	25 [51.0%]	01 [12.5%]	0.059	7.29	0.83-63.70
No	24 [49.0%]	07 [87.5%]			
Close contact with TB Patients					
Yes	50 [64.9%]	25 [32.5%]	<0.001	3.85	1.97-7.51
No	27 [35.1%]	52 [67.5%]			
Close contact with Drug Resistant TB patients					
Yes	39 [50.6%]	01 [1.3%]	0.001	78	10.31-589.62
No	38 [49.4%]	76 [98.7%]			
Response to TB treatment					
Positive	16 [20.8%]	26 [33.8%]	0.07	0.51	0.24 -1.06
Negative	61 [79.2%]	51 [66.2%]			
Experience of hospital stays					
Yes	69 [89.6%]	24 [31.2%]	<0.001	19.04	7.92-45.76
No	08 [10.4%]	53 [68.8%]			
Attended any TB counselling sessions					
Yes	42 [54.50%]	66 [85.70%]	<0.001	5	2.29-10.90
No	35 [45.50%]	11 [14.30%]			
HIV status					
Positive	5 [6.5%]	0 [0.0%]	0.02	-	
Negative	72 [93.5%]	77 [100.0%]			
Presence of other disease					
Yes	24 [31.2%]	19 [24.7%]	0.36	1.38	0.68-2.80
No	53 [68.8%]	58 [75.3%]			
Alcohol Consumption					
Yes	59 [76.6%]	53 [68.8%]	0.278	1.48	0.72-3.03
No	18 [23.4%]	24 [31.2%]			
Smoking					
Yes	40 [51.9%]	14 [18.2%]	<0.001	4.86	2.34-10.11
No	37 [48.1%]	63 [81.8%]			
Illicit Drug					
Yes	14 [18.2%]	2 [2.6%]	0.002	8.33	1.82-38.06
No	63 [81.8%]	75 [97.4%]			
Imprisonment					
Yes	3 [3.90%]	2 [2.60%]	1.00	1.52	0.24-9.36
No	74 [96.10%]	75 [97.40%]			

Social Isolation					
Yes	41 [53.2%]	47 [61.0%]	0.329	0.72	0.38-1.37
No	36 [46.8%]	30 [39.0%]			
I feel that I will lose friends and employment because I have TB					
Yes	57 [74.0%]	22 [28.6%]	<0.001	7.12	3.50-14.49
No	20 [26.0%]	55 [71.4%]			
People look at me differently because I have tuberculosis.					
Yes	60 [77.9%]	28 [36.4%]	<0.001	6.17	3.02-12.57
No	17 [22.1%]	49 [63.6%]			
I don't like other people to know that I have TB					
Yes	43 [55.8%]	53 [68.8%]	<0.001	0.57	0.29-1.10
No	34 [44.2%]	24 [31.2%]			
I consider myself nervous.					
Yes	59 [76.6%]	36 [46.8%]	<0.001	3.73	1.86-7.45
No	18 [23.4%]	41 [53.2%]			
Sometimes, I feel so sad that nothing can cheer me up					
Yes	45 [58.4%]	9 [11.7%]	<0.001	10.62	4.63-24.36
No	32 [41.6%]	68 [88.3%]			
Did something trouble you during the past 12 months?					
Yes	36 [46.8%]	11 [14.3%]	<0.001	5.26	2.41-11.48
No	41 [53.2%]	66 [85.7%]			
Despite of disease, I think I am happy.					
Yes	61 [79.20%]	68 [88.30%]	0.126	1.98	0.81-4.81
No	16 [20.80%]	9 [11.70%]			

323

324 After adjusting for the confounding factors, the final regression model [Table 6] showed that
 325 subjects infected with pulmonary tuberculosis were 14 times more at risk for MDR-TB than
 326 respondents with Extrapulmonary. Respondents who had previous TB treatment history were
 327 found to have more than 5-fold risk for MDR TB than those who were not previously treated.
 328 Similarly, respondents who were in close contact with DR-TB patients were found to be almost
 329 22 times the risk for MDR-TB. In addition, MDR-TB patients were more [OR= 42.33, CI 1.36-
 330 1315.4] likely to perceive subjective feeling of sadness.

331 Cases [Y] = $\beta_0 + \beta_1$ [PTB]+ β_2 [PH]+ β_3 [DR-TB-C] + β_4 [sad] Y= [- 5.342] + 2.6 + 1.622 +
 332 3.099 + 3.746
 333 Y= 5.725

334

335 This equation showed that one unit change in independent variables causes a 5.725 times
 336 change in dependent variables.

337 **Table 6 Multivariate analysis of factors associated with MDR TB**

Variables	Cat	β	P value	Odds Ratio	95% C.I. for OR	
					Lower	Upper

Tuberculosis Type	EPTB**	Ref.				
	PTB	2.69	0.004	14.7	2.321	93.54
Previous TB treatment History	No **					
	Yes	1.622	0.046	5.06	1.03	24.87
Close contact with DR TB patients	No**					
	Yes	3.099	0.015	22.18	1.829	269.1
Sometimes, I feel so sad that nothing can cheer me up	No**					
	Yes	3.746	0.033	42.35	1.364	1315.4
Constant		-5.342	0.013	0.005		

338

339 **: Reference, Cat: Categories, N= 154

340

341 Discussion

342

343 The study has provided relevant information about factors associated with MDR-TB, which
 344 can support activities being implemented to decrease the burden of TB in Nepal for
 345 policymakers. This study showed that Pulmonary Tuberculosis type, previous TB treatment
 346 history, close contact with DR-TB patients and subjective feelings of sadness were the strong
 347 predictors for MDR-TB.

348

349 Among sociodemographic factors, we identified that people residing in rural municipalities are
 350 more likely to develop MDR-TB than those living in urban areas [p=0.02], as supported by
 351 other studies(18,19). These data are alarming given the geographical features of our country
 352 like Nepal. Whereas the study conducted in Ukraine showed that the prevalence of RR/MDR-
 353 TB in the rural population was significantly lower than in the urban population at 20.9% and
 354 29.0%, respectively [P = 0.000](20). This study also showed migration as one of the risk factors
 355 of MDR-TB [P = 0.015, OR = 2.22, 95% CI 1.16-4.25]. The study conducted in China showed
 356 that MDR is more prevalent among migrants [odds ratios [OR] 1.32, 95% confidence interval
 357 [CI] 1.02–1.72](21); migration is considered an important contributor to missing cases and may
 358 lead to poor outcomes(22). To mitigate the number of migrants, it's essential to ensure uniform
 359 standards of care accessible nationwide, facilitated by robust communication channels such as
 360 telemedicine and referral systems. Additionally, implementing a unique identifier system
 361 would enable seamless patient connectivity across provinces and the entire nation.

362

363 This study showed that inadequate ventilation at home was a risk factor for MDR-TB [$p =$
364 0.01]. Poor ventilation and overcrowding have been documented as a risk factor for MDR-TB
365 in several other studies in a variety of settings as well(23,24). Likewise, those subjects who
366 lived in a house with no window or one window were almost two times more likely to develop
367 airborne infection compared to people whose house has multiple windows [AOR = 1.81; 95%
368 CI:1.06, 3.07](25), which may be due to the availability of favourable environment for MDR-
369 TB transmission. Therefore, advocating for adequate ventilation is crucial to disrupt the
370 transmission chain of MDR-TB.

371 Our study showed clinical features such as types of TB, previous TB treatment history, close
372 contact with TB and DR-TB patients, and experience of hospital stays as the risk factors of
373 MDR-TB with $p = 0.001$ for each factor. The majority of cases [89.6%]and controls [57.1%]
374 had Pulmonary Tuberculosis, which is similar to the study conducted in Ethiopia, with the
375 majority of participants having pulmonary TB in cases 141 [92.2%] and controls 137 [89.5%]
376 (26). We found that patients having Pulmonary Tuberculosis were more likely to develop
377 MDR-TB than those of Extra pulmonary TB patients, which is statistically significant in the
378 final binary logistic regression model with OR = 14.735, 95% CI [2.321-93.54], as confirmed
379 by the different studies in different countries; Germany(27), India(28) and Thailand(29).

380

381

382 This study showed previous TB treatment history was strongly associated with MDR-TB in
383 final regression model, with OR= 5.601 [95% CI, 1.03-24.876]. The increased proportion of
384 MDR-TB among previously treated cases has been indicated in various studies of various
385 settings(28–33); The rise in MDR-TB cases among previously treated individuals underscores
386 the urgency for higher quality treatment to prevent the development of drug resistance. Our
387 study showed that, 51.0% of MDR cases had interruption of TB treatment, which is similar to
388 the study conducted by Sanju B et al in 2017(34). We found patients with Interruption in TB
389 treatment were more likely to develop MDR-TB than those without TB-Treatment interruption
390 [$p= 0.059$, OR= 7.292, 95%CI 0.83-63.79], and another study also confirmed interruption of
391 treatment as a risk factors of MDR-TB [28,35–38]. Interruption of TB treatment promotes the
392 risk of bacterial mutations that eventually culminate in relapses and MDR- TB.

393 Our study showed that 64.9% of cases had history of contact with TB patient. Those who had
394 history of close contact with TB patients were more likely to develop MDR-TB than those
395 without close contact [$p<0.001$, OR=3.85, CI 1.974-71.5]. Several study conducted in different
396 settings also confirmed that close contact with TB patients is a risk factors of MDR-

397 TB[31,34,39], which is contrast to the study conducted in Ethiopia(40).
398 Similarly, Close contact with DR-TB patients was found to be a risk factor of MDR-TB. Final
399 regression model indicated that close contact with DR-TB patients increase the risk of MDR-
400 TB by 22.183 times [OR= 22.183,95% CI,1.829-268.12]. several studies documented close
401 contact with DR-TB as the major risk factors of MDR-TB(37,41,42), which is contrast to the
402 study conducted in Serbia (43).Our study showed that experience of hospital stays as a risk
403 factor of MDR-TB [p = 0.001] ie, patient who had hospitalization history were more likely to
404 develop MDR-TB than those who do not have previous history of hospital stay [p < 0.001,
405 OR= 19.047, 95% CI , 7.92-45.76], which is also documented in other studies(25,44). The
406 study conducted by v. Crudu et al documented that ,in 75% of cases, the MDR-TB strain was
407 genetically distinct from the non-MDR-TB strain at baseline, suggesting a high rate of
408 nosocomial transmission of MDR-TB(40). Proper infection control measures in health facilities
409 are crucial to protect other patients and healthcare workers, whereas preventive measures to
410 reduce transmission within community is required.

411
412 This study showed that not attending TB counselling sessions [p < 0.001, OR = 5, 95%CI 2.92-
413 10.90] is the risk factor for MDR-TB. One of the studies concluded that the Provision of
414 counselling and financial support may not only reduce their vulnerability but also increase cure
415 rates of MDR-TB(45). This study showed that smokers were more likely to develop MDR-TB
416 than non-smokers [p<0.001, OR=4.8, 95%CI 2.34-10.11], as confirmed by other studies
417 conducted in a different setting, china (46,47), Ethiopia(48), Lima Peru(49), Sudan(50), which
418 is a contrast to the study conducted in Addis Ababa (36), Nepal(51). Smoking had also affected
419 the global TB treatment success rate as shown in the study[65]. This study showed illicit drug
420 use as the risk factor of MDR- TB [P = 0.002, OR = 8.33, 95%CI 1.82-38.06], which is in
421 contrast to the study conducted in Canada(52) and Ethiopia(40). Engaging in illicit drug use
422 and smoking can disrupt the balance of the immune system, potentially heightening
423 susceptibility to infection.

424 This study showed that, stigma associated with TB as a risk factors of MDR-TB [p <0.001,
425 OR=0.72, 95%CI 0.38-1.37], which is similar to the study conducted in Serbia(43), china(47),
426 Nepal(45). It's imperative to safeguard and defend the rights of all individuals with
427 tuberculosis, as well as those most vulnerable to contracting the disease, Implementing policies
428 and practices aimed at shielding them from stigmatization and discrimination is essential(4).
429 There was significant difference in mental health of the respondents, this study showed
430 Significant difference between the both groups in persistence of subjective feeling of

431 nervousness [$P < 0.001$, $OR=3.77$, $95\%CI 1.86-7.45$], persistence of subjective feeling of
432 sadness [$p < 0.001$, $OR= 42.33$, $CI 1.36- 1315.4$] and experience of difficult situations in last
433 12 months [$p < 0.001$, $OR=5.26$ [2.416-11.488], which is similar to the study conducted in
434 Serbia (43). The study conducted in china also showed experience more life pressure/stress
435 [AOR, 10.8; 95% CI, 2.8–41.5] as the risk factors of MDR-TB(23)A life rejuvenation program
436 tailored for tuberculosis patients in high-risk areas is imperative. As the study covers a large
437 number of DR-TB cases in Nepal during the study period, the findings can be generalized.

438

439 **Strengths and Limitation**

440

441 Strengths of the study include collecting information on recent episodes of previous TB
442 treatment aimed at minimising recall bias. However, a notable limitation is the absence of data
443 on additional treatment episodes, particularly concerning patients with multidrug-resistant
444 tuberculosis [MDR-TB] who often undergo multiple treatments. Additionally, while the study
445 successfully achieved its objectives, it did not employ multiple data-gathering methods to
446 explore sensitive topics such as stigma and mental health issues. Notably, this study represents
447 the first attempt to investigate the risk factors of multidrug-resistant tuberculosis in three
448 districts of province number 3, which harbours the highest burden of DR-TB cases in Nepal,
449 favouring generalisation of findings.

450

451 **CONCLUSION**

452

453 This case-control study delved into factors associated with MDR-TB occurrence, identifying
454 Pulmonary Tuberculosis, prior TB treatment history, close contact with DR-TB patients, and
455 persistent subjective feelings of sadness as strong risk factors. The findings underscore the
456 necessity for quality treatment coupled with attentive monitoring to curb drug resistance
457 evolution among previously treated patients. Preventive measures should emphasize breaking
458 transmission chains within communities, bolstered by robust infection control measures in
459 healthcare facilities to minimize acquired MDR-TB cases among visitors, patients, and health
460 workers. Additionally, the study underscores the pressing need for life rejuvenation programs
461 targeting tuberculosis patients to safeguard their mental well-being.

462

463 **List of abbreviations**

464 AMR : Anti-Microbial Resistance, AOR : Adjusted Odds Ratio, BPKIHS : B.P. Koirala

465 Institute of Health Sciences, CAT-I : Category I, CI : Confidence Interval, COPD :
466 Chronic Obstructive Pulmonary Diseases, DOTS : Directly Observed Treatment Short
467 Course, DR-TB : Drug-Resistant Tuberculosis, DST : Drug Susceptibility Test, DS-TB :
468 Drug-Susceptible Tuberculosis, EPTB : Extra Pulmonary Tuberculosis, HF : Health
469 Facility, HIV/AIDS : Human Immunodeficiency Virus/Acquired Immunodeficiency
470 Syndrome, HR : Isoniazid, Rifampicin, HRZE : Isoniazid, Rifampicin, Pyrazinamide,
471 Ethambutol, HRZELfx : Isoniazid, Rifampicin, Pyrazinamide, Ethambutol, Levofloxacin,
472 JANTRA : Japan Nepal Health and Tuberculosis Research Association, LPA : Line Probe
473 Assay, LR-1 : Longer Regiment I, LR-2 : Longer Regiment II, LR-3 : Longer Regiment
474 III, LTBI : Latent Tuberculosis Infection, M. Tuberculosis : Mycobacterium Tuberculosis,
475 MDR-TB : Multi-Drug-Resistant Tuberculosis, MDR/RR-TB : Multi-Drug-Resistant
476 Rifampicin-Resistant Tuberculosis, NATA : Nepal Anti Tuberculosis Association, NTC :
477 National Tuberculosis Center, OR : Odds Ratio, PLS-PM : Partial Least Square Path
478 Modelling, PTB : Pulmonary Tuberculosis, RR/MDR : Rifampicin-Resistant/Multi-Drug-
479 Resistant, SDG : Sustainable Development Goals, SEAR : South East Asia Region, SPSS
480 : Statistical Package for the Social Sciences, SSTR : Shorter Standardized Treatment
481 Regimen, TB : Tuberculosis, TPT : Tuberculosis Preventive Therapy, TSR : Treatment
482 Success Rate, WHO : World Health Organization, XDRTB : Extremely Drug-Resistant
483 Tuberculosis

484

485 **Acknowledgements**

486 The authors would like to acknowledge Dr Suvesh Kumar Shrestha for his valuable insights
487 and sincerely thank all the participants.

488

489 **Author's contribution**

490 **Conceptualisation:** Puspa Acharya, Niraj Bhattarai, Vijay Kumar Khanal

491 **Data curation:** Puspa Acharya, Niraj Bhattarai , Dr Bhuban Raj Kunwar ,Birendra Kuma
492 Yadav,

493 **Formal analysis:** Puspa Acharya, Niraj Bhattarai , Khem Raj Sharma

494 **Methodology:** Puspa Acharya, Niraj Bhattarai, Dr Bhuban Raj Kunwar

495 **Supervision:** Vijay Kumar Khanal, Birendra Kuma Yadav, Khem Raj Sharma , Dr Bhuban
496 Raj Kunwar

497 **Validation:** Vijay Kumar Khanal, Birendra Kuma Yadav, Khem Raj Sharma , Dr Bhuban Raj

498 Kunwar

499 **Writing original draft:** Puspa Acharya, Niraj Bhattarai

500 **Writing-review and editing:** Puspa Acharya, Niraj Bhattarai, Dr Bhuban Raj Kunwar

501 **Conflicts of interest**

502 Authors declare no conflicts of interest.

503 **Funding**

504 Authors receive no funding for this study.

505 **Ethics**

506 The study was conducted from March 2021 to August 2021. Ethical approval was obtained
507 from the Institutional Review Committee [IRC] of BP Koirala Institute of Health Sciences
508 [BPKIHS], Dharan, dated 18 Feb 2021, with IRC No. Acd/597. An original copy of the ethical
509 approval is submitted as supplementary files. Verbal consent was obtained from the
510 participants, and the study maintained their anonymity.

511

512 **Supporting Information**

513 S 1: Original copy of ethical approval from the Institutional Review Committee.

514

515 **References**

516

517

518 1. WHO. Global tuberculosis report 2019. Geneva: World Health Organization; 2019.

519 Licence: CC BY-NC-SA 3.0 IGO. 2019.

520 2. Rock D. Tuberculosis: a global emergency. *Work* [Internet]. 1997;8(1):93–105.

521 Available from:

522 [https://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/WOR-](https://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/WOR-1997-8111)
523 [1997-8111](https://www.medra.org/servlet/aliasResolver?alias=iospress&doi=10.3233/WOR-1997-8111)

524 3. World Health Organization. What is DOTS ? A Guide to Understanding the WHO-
525 recommended TB Control Strategy Known as DOTS. *Prev Control* [Internet]. 1999;1–
526 39. Available from: <https://apps.who.int/iris/handle/10665/65979>

527 4. Reid MJA, Arinaminpathy N, Bloom A, Bloom BR, Boehme C, Chaisson R, et al.
528 Building a tuberculosis-free world: The Lancet Commission on tuberculosis. *Lancet*
529 [Internet]. 2019 Mar;393(10178):1331–84. Available from:

530 <https://linkinghub.elsevier.com/retrieve/pii/S0140673619300248>

531 5. WHO. Follow-up to the high-level meetings of the UN General Assembly on health-

- 532 related issues AMR Report by the Director-General. Seventy-second World Heal
533 Assem [Internet]. 2019;(April):1–11. Available from: <https://amrcountryprogress.org>.
- 534 6. Tb D. Focus on Drug-resistant Tuberculosis. Glob Fund 2019 [Internet]. 2019;
535 Available from: [https://www.theglobalfund.org/media/6651/publication_drug-
536 resistanttuberculosis_focuson_en.pdf?u=63645035838000000](https://www.theglobalfund.org/media/6651/publication_drug-resistanttuberculosis_focuson_en.pdf?u=63645035838000000)
- 537 7. Law S, Piatek AS, Vincent C, Oxlade O, Menzies D. Emergence of drug resistance in
538 patients with tuberculosis cared for by the Indian health-care system: a dynamic
539 modelling study. *Lancet Public Heal* [Internet]. 2017;2(1):e47–55. Available from:
540 [http://dx.doi.org/10.1016/S2468-2667\(16\)30035-4](http://dx.doi.org/10.1016/S2468-2667(16)30035-4)
- 541 8. GON, MOHP, DOHS, NTCC. National Tuberculosis Program Nepal. NTCC, editor.
542 Vol. 75, Annual Report. Bhaktapur: NTC; 2018. 1–30 p.
- 543 9. World Health Organization. Consolidated Guidelines on Tuberculosis Treatment.
544 Who. 2019.
- 545 10. Ending TB: Invest Now or Pay Later. New Delhi: World Health Organization,
546 Regional Office for South-East Asia; 2018. Licence: CC BY-NC- SA 3.0 IGO. 2018;
- 547 11. Hwang SS, Kang S, Lee JY, Lee JS, Kim HJ, Han SK, et al. Impact of outdoor air
548 pollution on the incidence of tuberculosis in the Seoul metropolitan area, South Korea.
549 *Korean J Intern Med*. 2014;29(2):183–90.
- 550 12. WHO. ENDING TB IN SEAR, Regional strategic plan 2016-2020. Vol. 53, Journal of
551 Chemical Information and Modeling. 2013. 1689–1699 p.
- 552 13. Institute of Health Metrix and Evaluations [IHME]. Findings from the Global Burden
553 of Disease Study 2017. Seattle, WA: IHME, 2018. *Lancet*. 2017;
- 554 14. The Economist Intelligence Unit. It ’s Time to End Drug-Resistant Tuberculosis. The
555 case for action. 2019;1–39. Available from:
556 [http://www.eiu.com/graphics/marketing/pdf/its-time-to-end-drug-resistant-
557 tuberculosis-full-report.pdf](http://www.eiu.com/graphics/marketing/pdf/its-time-to-end-drug-resistant-tuberculosis-full-report.pdf)
- 558 15. Bhatia V, Srivastava R, Reddy KS, Sharma M, Mandal PP, Chhabra N, et al. Ending
559 TB in Southeast Asia: Current resources are not enough. *BMJ Glob Heal*. 2020;5(3):1–
560 11.
- 561 16. Shrestha SK, Shah NP, Jha KK, Pant RP, Joshi LR, Bichha RP, et al. Challenges in the
562 diagnosis of drug-resistant tuberculosis by GeneXpert MTB/Rif in Nepal. *SAARC J
563 Tuberc Lung Dis HIV/AIDS*. 2018;16(2):8–15.
- 564 17. Comolet T. La tuberculose à bacilles multi-résistants : défis d’une émergence globale.
565 *Bull la Soc Pathol Exot*. 2015;108(4):290–8.

- 566 18. Abdella K, Abdissa K, Kebede W, Abebe G. Drug resistance patterns of
567 Mycobacterium tuberculosis complex and associated factors among retreatment cases
568 around Jimma, Southwest Ethiopia. *BMC Public Health* [Internet]. 2015 Jul 2 [cited
569 2021 Mar 9];15(1):599. Available from:
570 <http://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-015-1955-3>
- 571 19. Ali MH, Alrasheedy AA, Hassali MA, Kibuule D, Godman B. Predictors of multidrug-
572 resistant tuberculosis (MDR-TB) in Sudan. *Antibiotics*. 2019 Sep 1;8(3).
- 573 20. Korotych O, Hovhannisyann A, Zaitseva O, Denisuk O, Dadu A, Dara M. Risk factors
574 associated with RR/MDR-TB among new pulmonary tuberculosis patients in urban
575 and rural areas of Ukraine in 2017: retrospective analysis of routine surveillance data.
576 *Public Heal Panor*. 2019;5(4):536–47.
- 577 21. Liu L, Zhang X, Zhao L, Li N. Empirical analysis of the status and influencing factors
578 of catastrophic health expenditure of migrant workers in Western China. *Int J Environ*
579 *Res Public Health*. 2019;16(5):1–10.
- 580 22. Ismail N, Ismail F, Omar S V., Blows L, Gardee Y, Koornhof H, et al. Drug resistant
581 tuberculosis in Africa: Current status, gaps and opportunities. *Afr J Lab Med*.
582 2018;7(2):1–11.
- 583 23. Li W Bin, Zhang YQ, Xing J, Ma ZY, Qu YH, Li XX. Factors associated with primary
584 transmission of multidrug-resistant tuberculosis compared with healthy controls in
585 Henan Province, China. *Infect Dis Poverty* [Internet]. 2015 Mar 24 [cited 2021 Mar
586 8];4(1):14. Available from:
587 <https://idpjournal.biomedcentral.com/articles/10.1186/s40249-015-0045-1>
- 588 24. Escombe AR, Oeser CC, Gilman RH, Navincopa M, Ticona E, Pan W, et al. Natural
589 Ventilation for the Prevention of Airborne Contagion. *PLOS Med* [Internet]. 2007
590 [cited 2021 Mar 9];4(2):e68. Available from:
591 <https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0040068>
- 592 25. Shimeles E, Enquesselassie F, Aseffa A, Tilahun M, Mekonen A, Wondimagegn G, et al.
593 Risk factors for tuberculosis: A case–control study in Addis Ababa, Ethiopia. *PLoS*
594 *One*. 2019;14(4):1–18.
- 595 26. Mulu W, Mekonnen D, Yimer M, Admassu A, Abera B. Risk factors for multidrug
596 resistant tuberculosis patients in amhara national regional state. *Afr Health Sci*.
597 2015;15(2):368–77.
- 598 27. Glasauer S, Altmann D, Hauer B, Brodhun B, Haas W, Perumal N. First-line
599 tuberculosis drug resistance patterns and associated risk factors in Germany, 2008-

- 600 2017. *PLoS One*. 2019;14(6):2008–17.
- 601 28. Gaude G, Hattiholli J, Kumar P. Risk factors and drug-resistance patterns among
602 pulmonary tuberculosis patients in northern Karnataka region, India. *Niger Med J*
603 [Internet]. 2014 [cited 2021 Mar 9];55(4):327. Available from:
604 <http://www.nigeriamedj.com/text.asp?2014/55/4/327/137194>
- 605 29. Chuchottaworn C, Thanachartwet V, Sangsayunh P, Than TZM, Sahassananda D,
606 Surabotsophon M, et al. Risk Factors for Multidrug-Resistant Tuberculosis among
607 Patients with Pulmonary Tuberculosis at the Central Chest Institute of Thailand.
608 Munderloh UG, editor. *PLoS One* [Internet]. 2015 Oct 7 [cited 2021 Mar
609 9];10(10):e0139986. Available from:
610 <https://dx.plos.org/10.1371/journal.pone.0139986>
- 611 30. Isaakidis P, Das M, Kumar AMV, Peskett C, Khetarpal M, Bamne A, et al. Alarming
612 levels of drug-resistant tuberculosis in HIV-infected patients in metropolitan Mumbai,
613 India. *PLoS One*. 2014 Oct 21;9(10):e110461.
- 614 31. Baya B, Achenbach CJ, Kone B, Toloba Y, Dabita DK, Diarra B, et al. Clinical risk
615 factors associated with multidrug-resistant tuberculosis (MDR-TB) in Mali. *Int J Infect*
616 *Dis* [Internet]. 2019 Apr 1 [cited 2021 Mar 9];81:149–55. Available from:
617 <https://doi.org/10.1016/j.ijid.2019.02.004>
- 618 32. Eshetie S, Gizachew M, Dagne M, Kumera G, Woldie H, Ambaw F, et al. Multidrug
619 resistant tuberculosis in Ethiopian settings and its association with previous history of
620 anti-tuberculosis treatment: A systematic review and meta-analysis. *BMC Infect Dis*.
621 2017 Mar 20;17(1).
- 622 33. Su WJ, Feng JY, Huang CC, Perng RP. Increasing drug resistance of *Mycobacterium*
623 tuberculosis isolates in a medical center in northern Taiwan. *J Formos Med Assoc*.
624 2008 Mar 1;107(3):259–64.
- 625 34. B S, A S. Contributing Factors Associated with Multi-Drugs Resistance Tuberculosis
626 among MDR-TB Clients of Kathmandu, Nepal. *Int J Heal Sci Res*. 2017;7(july):164–
627 70.
- 628 35. Khan MS, Hutchison C, Coker RJ, Yoong J, Hane KM, Innes AL, et al. Preventing
629 emergence of drug resistant tuberculosis in Myanmar’s transitioning health system.
630 *Health Policy Plan*. 2017;32:ii43–50.
- 631 36. Hirpa S, Medhin G, Girma B, Melese M, Mekonen A, Suarez P, et al. Determinants of
632 multidrug-resistant tuberculosis in patients who underwent first-line treatment in Addis
633 Ababa: A case control study. *BMC Public Health*. 2013;13(1):1–9.

- 634 37. Gobena D, Ameya G, Haile K, Abreha G, Worku Y, Debela T. Predictor of multidrug
635 resistant tuberculosis in southwestern part of Ethiopia: A case control study. *Ann Clin*
636 *Microbiol Antimicrob*. 2018 Jul 3;17(1).
- 637 38. Moyo S, Cox HS, Hughes J, Daniels J, Synman L, De Azevedo V, et al. Loss from
638 treatment for drug resistant tuberculosis: Risk factors and patient outcomes in a
639 community-based program in khayelitsha, South Africa. *PLoS One*. 2015;10(3):1–13.
- 640 39. Demile B, Zenebu A, Shewaye H, Xia S, Guadie A. Risk factors associated with
641 multidrug-resistant tuberculosis (MDR-TB) in a tertiary armed force referral and
642 teaching hospital, Ethiopia. *BMC Infect Dis*. 2018 May 31;18(1).
- 643 40. Workicho A, Kassahun W, Alemseged F. Risk factors for multidrug-resistant
644 tuberculosis among tuberculosis patients: A case-control study. *Infect Drug Resist*.
645 2017 Mar 13;10:91–6.
- 646 41. Mulu W, Mekonnen D, Yimer M, Admassu A, Abera B. Risk factors for multidrug
647 resistant tuberculosis patients in amhara national regional state. *Afr Health Sci*
648 [Internet]. 2015 [cited 2021 Mar 9];15(2):368–77. Available from:
649 [/pmc/articles/PMC4480497/](https://pubmed.ncbi.nlm.nih.gov/274480497/)
- 650 42. Guenaoui K, Harir N, Ouardi A, Zeggai S, Sellam F, Bekri F, et al. Use of GeneXpert
651 *Mycobacterium tuberculosis*/rifampicin for rapid detection of rifampicin resistant
652 *Mycobacterium tuberculosis* strains of clinically suspected multi-drug resistance
653 tuberculosis cases. *Ann Transl Med*. 2016 May 1;4(9):168.
- 654 43. Stosic M, Vukovic D, Babic D, Antonijevic G, Foley KL, Vujcic I, et al. Risk factors
655 for multidrug-resistant tuberculosis among tuberculosis patients in Serbia: A case-
656 control study. *BMC Public Health* [Internet]. 2018 Sep 12 [cited 2021 Mar
657 9];18(1):1114. Available from:
658 <https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-018-6021-5>
- 659 44. Mesfin EA, Beyene D, Tesfaye A, Admasu A, Addise D, Amare M, et al. Drug-
660 resistance patterns of mycobacterium tuberculosis strains and associated risk factors
661 among multi drug-resistant tuberculosis suspected patients from Ethiopia. *PLoS One*.
662 2018;13(6):1–16.
- 663 45. Baral SC, Aryal Y, Bhattra R, King R, Newell JN. The importance of providing
664 counselling and financial support to patients receiving treatment for multi-drug
665 resistant TB: Mixed method qualitative and pilot intervention studies. *BMC Public*
666 *Health* [Internet]. 2014 Jan 17 [cited 2021 Mar 15];14(1):46. Available from:
667 [http://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-14-46](https://bmcpublichealth.biomedcentral.com/articles/10.1186/1471-2458-14-46)

- 668 46. Tang S, Tan S, Yao L, Li F, Li L, Guo X, et al. Risk factors for poor treatment
669 outcomes in patients with MDR-TB and XDR-TB in China: Retrospective multi-center
670 investigation. *PLoS One*. 2013;8(12):1–8.
- 671 47. Zhang C, Wang Y, Shi G, Han W, Zhao H, Zhang H, et al. Determinants of multidrug-
672 resistant tuberculosis in Henan province in China: a case control study. *BMC Public*
673 *Health*. 2016 Jan 16;16(1):42.
- 674 48. Welekidan LN, Skjerve E, Dejene TA, Gebremichael MW, Brynildsrud O, Agdestein
675 A, et al. Characteristics of pulmonary multidrug-resistant tuberculosis patients in
676 Tigray Region, Ethiopia: A cross-sectional study. Quinn F, editor. *PLoS One*
677 [Internet]. 2020 Aug 14 [cited 2021 Mar 9];15(8):e0236362. Available from:
678 <https://dx.plos.org/10.1371/journal.pone.0236362>
- 679 49. Chung-Delgado K, Revilla-Montag A, Guillen-Bravo S, Velez-Segovia E, Soria-
680 Montoya A, Nuñez-Garbin A, et al. Factors associated with anti-tuberculosis
681 medication adverse effects: A case-control study in Lima, Peru. *PLoS One*.
682 2011;6(11):1–5.
- 683 50. Elduma AH, Mansournia MA, Foroushani AR, Ali HMH, Elegail AMA, Elsony A, et
684 al. Assessment of the risk factors associated with multidrug-resistant tuberculosis in
685 Sudan: a case-control study. *Epidemiol Health*. 2019;41:e2019014.
- 686 51. Bichha RP, Jha KK, Salhotra VS, Weerakoon AP, Karki KB, Bichha N. An
687 Epidemiological Study to Find out Risk Factors of Multi Drugs Resistance
688 Tuberculosis in Nepal. *SAARC J Tuberc Lung Dis HIV/AIDS*. 2018;14(2):31–8.
- 689 52. Hiramata T, Sabur N, Derkach P, McNamee J, Song H, Marras T, et al. Risk factors for
690 drug-resistant tuberculosis at a referral centre in Toronto, Ontario, Canada: 2010–
691 2016. *Canada Commun Dis Rep*. 2020 Apr 2;46(04):84–92.
- 692
693
694